


# Phosphate Replacement Guideline



## PHOSPHATE

|                                 |   |
|---------------------------------|---|
| <b>PRESENTATION:</b>            | <p>Addiphos 20ml vials containing 40mmol phosphate, 30mmol sodium and 30mmol potassium.</p> <p>Phosphate 500ml polyfusor containing 50mmol phosphate, 9.5mmol potassium and 81mmol sodium.</p> <p>Potassium acid phosphate 10ml ampoules containing 10mmol phosphate (1mmol/ml) and 10mmol potassium.</p> <p>Sodium glycerophosphate 20ml ampoules containing 20mmol phosphate (1mmol/ml) and 40mmol sodium.</p>  |
| <b>INDICATION:</b>              | <p>Hypophosphataemia.</p> <p>See previous page.</p>   |
| <b>DOSE AND ADMINISTRATION:</b> | <p><b>Addiphos:</b></p> <ul style="list-style-type: none"> <li>- Central IV administration: 20ml Addiphos made up to 60ml with glucose 5% over 6 hours.</li> <li>- Peripheral IV administration 20ml Addiphos made up to 500ml with glucose 5% over 6 hours.</li> </ul> <p><b>Phosphate polyfusor:</b></p> <ul style="list-style-type: none"> <li>- Central or peripheral IV administration: 500ml polyfusor administered over 12 hours (Can be given centrally over 6 hours if required).</li> </ul> <p>If hypernatraemia a concern:<br/><b>Potassium Acid Phosphate</b></p> <ul style="list-style-type: none"> <li>- Central IV administration: 40ml made up to 60ml with glucose 5% over 6 hours.</li> </ul> <p>If hyperkalaemia a concern:<br/><b>Sodium Glycerophosphate:</b></p> <ul style="list-style-type: none"> <li>- Central IV administration: 40ml made up to 60ml with glucose 5% over 6 hours.</li> <li>- Peripheral IV administration: 40ml made up to 500ml with glucose 5% over 8 hours.</li> </ul> |
| <b>STABILITY:</b>               | Physically and chemically stable for 24 hours at room temperature.  |

## References:

- 1) UKCPA Minimum Infusion Volumes, Fourth Edition, December 2012. Accessed December 2020. <https://www.scottishintensivecare.org.uk/uploads/2014-07-24-19-56-30-Minimuminfusionvolumesinl-40262.pdf>
- 2) Injectable Medicines Guide, Medusa, accessed December 2020. <https://medusa.wales.nhs.uk/Home.asp>
- 3) Sodium Glycerophosphate, Summary of product characteristics, Fresenius Kabi. Updated March 2017. Accessed December 2020. [https://www.fresenius-kabi.com/nz/documents/Glycophos\\_Datasheet.pdf](https://www.fresenius-kabi.com/nz/documents/Glycophos_Datasheet.pdf)
- 4) Sterile Potassium Acid Phosphate, Martindale Pharmaceuticals, SPC, updated January 2015. Accessed December 2020. <https://www.medicines.org.uk/emc/product/3572/smpc#gref>
- 5) Anecdotal experience in Critical Care units in NHS Lothian since 2010.
- 6) Personal communication with Fresenius-Kabi Medicines Information regarding stability of products 02/2014.
- 7) Personal communication with Fresenius –Kabi Medicines Information regarding stability of products 09/2015.

|                                  |  |
|----------------------------------|--|
| <b>Title:</b> Phosphate          |  |
| <b>ID:</b> Version 3             | <b>Authors:</b> E Tang, C Hannah, G Smyth, A Neally, M Cromarty, H Veitch. |
| <b>Status Draft/Final:</b> FINAL | <b>Approved by:</b> Lothian Critical Care QIT Editorial Group.             |
|                                  | <b>Written:</b> January 2022   |
| <b>Updated on:</b> January 2022  | <b>Next review :</b> January 2024  |